

Invasive Therapy for Cervicogenic Headache

Submission date 08/08/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 10/08/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 07/01/2021	Condition category Signs and Symptoms	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Wim Weber

Contact details
Dept. Neurology
University Hospital Maastricht
P.O. Box 5800
Maastricht
Netherlands
6202 AZ
+31 (0)43 3875117
wweb@neurologie.azm.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Invasive Therapy for Cervicogenic Headache

Acronym

ITCH

Study objectives

A sequence of cervical radiofrequency lesions (directed at the cervical facet joints, eventually followed by dorsal root ganglion lesions) is more effective than conservative therapy (local injections with anaesthetic and methylprednisolone of the greater occipital nerve, eventually followed by transcutaneous nerve stimulation) in alleviating headache in patients with cervicogenic headache

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet**Health condition(s) or problem(s) studied**

Cervicogenic headache

Interventions

Radiofrequency neurotomy of the cervical facet joint, eventually followed by a radiofrequency lesion of a cervical dorsal root ganglion versus conservative therapy (local injections with anaesthetic and methylprednisolone of the greater occipital nerve, eventually followed by transcutaneous nerve stimulation)

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Methylprednisolone

Primary outcome measure

Mean visual analogue scores of pain at 8 weeks, 3-months, 6-months and 1 year

Secondary outcome measures

Global perceived effect by patient at the above-mentioned timepoints. The number of headache days, the medicine use and the headache intensity during a week were also recorded.

Overall study start date

01/09/1997

Completion date

01/07/2002

Eligibility**Key inclusion criteria**

The study group was recruited from patients with cervicogenic headache (CH) according to the diagnostic criteria of Sjaastad. The other following inclusion criteria had to be fulfilled:

1. Age between 20 and 65 years; chronic cervicogenic headache of more than 2 years' duration
2. An initial visual analogue scale (VAS) score of more than 50 mm during a pain period
3. A significant pain during at least two days per week
4. At least one of the following symptoms on physical examination of the neck: paravertebral tenderness on palpation of the cervical spine and/or positive tender points at specific points indicating the involvement of segmental nerves and/or reduction of range of motion in the cervical spine

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

30

Total final enrolment

30

Key exclusion criteria

Excluded from the study were patients who had previous surgical procedures of the cervical spine; who had coagulation disturbances; who were pregnant; who had multilevel severe degenerative changes; who were diagnosed with post-whiplash syndrome and in whom none of the symptoms on physical examination described above were present.

Date of first enrolment

01/09/1997

Date of final enrolment

01/07/2002

Locations

Countries of recruitment

Netherlands

Study participating centre**Dept. Neurology**

Maastricht

Netherlands

6202 AZ

Sponsor information

Organisation

University Hospital Maastricht, Pain Centre (The Netherlands)

Sponsor details

P.O. Box 5800

Maastricht

Netherlands

6202 AZ

+31 (0)43 3876543

pijn@sane.azm.nl

Sponsor type

University/education

Website

<http://www.pijn.com>

ROR

<https://ror.org/02d9ce178>

Funder(s)

Funder type

University/education

Funder Name

University Hospital Maastricht, Pain Centre (Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	16/02/2006		Yes	No